Latest News in the pharma Industry

Research & Development

Kalytera submits Phase II study protocol to IRBs for cannabidiol in the prevention of GvHD

Kalytera submits Phase II study protocol to IRBs for cannabidiol in the prevention of GvHD

14 Aug 2017

The Phase II study is designed to generate the pharmacokinetic and safety data, at multiple dose levels, that will be required by the FDA.

Read more 
FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial

FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial

14 Aug 2017

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

Read more 
Experimental treatment for Niemann-Pick disease type C1 appears safe, effective

Experimental treatment for Niemann-Pick disease type C1 appears safe, effective

13 Aug 2017

NIH-led clinical trial suggests that drug slows progression of rare neurological disease.

Read more 
Major progress in next generation medicines initiative

Major progress in next generation medicines initiative

10 Aug 2017

Juniper Pharma Services now has CrystecPharma’s supercritical fluid technology platform on-site.

Read more 
NCI study identifies essential genes for cancer immunotherapy

NCI study identifies essential genes for cancer immunotherapy

7 Aug 2017

This knowledge could speed the development of a new category of drugs.

Read more 
AbbVie's Mavyret receives FDA approval for the treatment of chronic hepatitis C

AbbVie's Mavyret receives FDA approval for the treatment of chronic hepatitis C

6 Aug 2017

FDA approval is supported by an overall 98% cure rate in patients who received the recommended duration of treatment .

Read more 
IDT launches first Cas9 enzyme that drastically reduces CRISPR off-target effects without significant loss of on-target activity

IDT launches first Cas9 enzyme that drastically reduces CRISPR off-target effects without significant loss of on-target activity

3 Aug 2017

The launch represents a major step towards therapeutic use of CRISPR.

Read more 
BMS receives FDA approval for Opdivo Injection for metastatic colorectal cancer

BMS receives FDA approval for Opdivo Injection for metastatic colorectal cancer

3 Aug 2017

Approval based on CheckMate -142, in which Opdivo demonstrated an objective response rate of 28% among patients who received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Read more 
Amgen submits sBLA for Prolia in glucocorticoid-induced osteoporosis

Amgen submits sBLA for Prolia in glucocorticoid-induced osteoporosis

31 Jul 2017

Results from the Phase III study included in the sBLA submission showed that treatment with Prolia for 12 months led to statistically significant greater gains in BMD at the lumbar spine and total hip compared to risedronate.

Read more 
BMS and Clovis Oncology announce a broad clinical collaboration to evaluate combination of Opdivo and Rubraca

BMS and Clovis Oncology announce a broad clinical collaboration to evaluate combination of Opdivo and Rubraca

31 Jul 2017

Pivotal Phase III trials planned for 2017 will evaluate Rubraca + Opdivo, Rubraca as monotherapy, and Opdivo as monotherapy in first line maintenance treatment for advanced ovarian and advanced triple-negative breast cancers.

Read more 
Arch Biopartners' GMP manufacturing of AB569 on schedule

Arch Biopartners' GMP manufacturing of AB569 on schedule

30 Jul 2017

Dalton Pharma Services is preparing glass vials in three varying dose formulations for the clinical kits needed to support the Phase I safety trial for AB569 at the CVAMC later this year.

Read more 
Boehringer starts clinical study on interchangeability between adalimumab biosimilar candidate and US-formulated Humira

Boehringer starts clinical study on interchangeability between adalimumab biosimilar candidate and US-formulated Humira

30 Jul 2017

First study in the US to investigate an interchangeability designation for an adalimumab biosimilar candidate.

Read more